Sociedad Americana de Hirudoterapia

Leech Pancreatic Trypsin Inhibitor Variant (LPTI-2)

Bovine pancreatic trypsin inhibitor (Kunitz)-family homolog identified in Hirudo medicinalis sialotranscriptome — sister to LPTI / LCI.

Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Leech Pancreatic Trypsin Inhibitor Variant (LPTI-2) compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaLeech Pancreatic Trypsin Inhi…6.5 kDa
Molecular weight (kilodaltons) of Leech Pancreatic Trypsin Inhibitor Variant (LPTI-2) (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Bovine pancreatic trypsin inhibitor (Kunitz)-family homolog identified in Hirudo medicinalis sialotranscriptome — sister to LPTI / LCI.
Evidence level
In vitro
Drug vs leech
Purified natural compound

Clinical translation limit

This Kunitz-domain inhibitor variant has not been clinically translated. No FDA-approved derivative exists; the broader Kunitz class includes aprotinin, which is unrelated and derived from bovine pancreas.

Molecular Profile

Category
Proteinase Inhibitor
Evidence tier
Preclinical
Molecular weight
6,500 Da
Source species
Hirudo medicinalis
Discovered
2018
Leech Pancreatic Trypsin Inhibitor Variant (LPTI-2) molecular structure

Biological Targets

  • trypsin
  • chymotrypsin
  • kallikrein

External Resources

    Related Proteinase Inhibitor Compounds

    Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.